articleThe Lancet OncologyFeb 22, 2009GREEN OA

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

PFPierre FenauxGJGhulam J. MuftiEHEva Hellström‐LindbergVSValeria SantiniCFCarlo Finelli

Université Sorbonne Paris Nord · Hôpital Avicenne · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,636
total citations
FWCI
94.37
Percentile
100%
References
49
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Medicine
  • Azacitidine
  • Internal medicine
  • Hazard ratio
  • Clinical endpoint
  • Myelodysplastic syndromes
  • Randomized controlled trial
  • International Prognostic Scoring System
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding